Skip to content
MCPHS Faculty Jennifer Goldman-Levine

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP

Professor of Pharmacy Practice, Clinical Pharmacist, Well Life

Department: Pharmacy Practice
Office: White 347

Contact: jennifer.goldman@mcphs.edu
(P) 617.732.2917



Schools

School of Pharmacy

Programs

Pharmacy (PharmD)

Education

Pharmacy Practice Residency, Specialty in Ambulatory Care; Boston VA Medical Center
PharmD, Massachusetts College of Pharmacy and Health Sciences, 1996
BS, Pharmacy, Massachusetts College of Pharmacy and Health Sciences, 1990


Research Interests

Diabetes
Cardiovascular disease
Scholarship of teaching


Peer-Reviewed Articles & Book Chapters

Goldman JD, Patel D, Shah V. Basal insulin therapy in type 2 diabetes management: What the pharmacist should know. Pharmacy Times, September 2021. Published ahead of print. Available online at: https://www.pharmacytimes.com/view/basal-insulin-therapy-in-type-2-diabetes-management-what-the-pharmacist-should-know.

Nigro S, Goldman JD. Linagliptin-induced arthralgia. https://doi.org/10.2337/cd20-0110 Published ahead of print. Clinical Diabetes. 2021 Jul;cd20010.

Khzouz A, Rickson M, Sieradzan R, Goldman JD. Injection force variability: An overlooked aspect of proper insulin injection technique. doi.org/10.1177/2633559X20972353. ADCES in Practice. 2021;9(2);42-47.

Shealy KM, Phillisps CM, Bzowyckyi AS, Gupta V, Guyton J, Westberg SM, Cai C, Trujillo J, Goldman JD. Endocrine pharmacotherapy education in United States colleges and schools of pharmacy. J Am Coll Clin Pharm. 2021:1-9. doi-org.ezproxymcp.flo.org/10.1002/jac5.1393. Published ahead of print February 2021. J Am Coll Clin Pharm. 2021;4:481-489.

Pass A, Bialonczyk D, Chiquette E, Goldman JD. Oral superabsorbent hydrogel (Plenity) for weight management. Ann Pharmacother. doi.org/10.1177/1060028020983046. Published ahead of print, December, 2020.

Goldman JD. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics. doi.org/10.1111/jcpt.3226. Published online ahead of print, September 2020.

Schumacher C, Van Dril E, Shealy K, Goldman JD. Optimizing management of type 2 diabetes and its complications in patients with heart failure. Clinical Diabetes. doi.org/10.2337/cd20-0008 . Published online ahead of print, August 2020.

Goldman JD, Harte F. Transition of care to prevent recurrence after acute coronary syndrome; the critical role of the primary care provider and pharmacist. Postgraduate Medicine. doi.org/10.1080/00325481.2020.1740512. Published online ahead of print, March 2020.

Lu B, Goldman JD. Glucose variability and the use of continuous glucose monitors in people with type 1 and type 2 diabetes. Published ahead of print, AADE in Practice. October 2018. 2018;6(6):22-25. AADE in Practice. 2018;6(6):22-25.

Morse C, Sze D, Patel D, Goldman JD. Non-glycemic benefits of antidiabetic medications. Published ahead of print, Clinical Diabetes, October 2018. Clinical Diabetes. 2018;37(2):131-141.

Goldman JD, Gill J, Horn T, Reid T, Strong J, Polonsky W. Improved treatment engagement among patients treated with insulin glargine 300U/ml who received live support through the COACH support program. . Diabetes Ther. 2018;9(5):2143-2153.

White J, Goldman JD. Biosimilar and follow-on insulin: The ins, outs and interchangeability. Published ahead of print, Journal of Pharmacy Technology, September 2018. J Pharm Technol. 2019;35(1): 25–35.

Goldman JD. Antihyperglycemic medications for cardiovascular disease risk reduction. Am J Manag Care. 2018;24-S273-S278.

Sze D, Goldman JD. Human regular 500 units/ml insulin therapy. A review of clinical evidence and new delivery options. Clinical Diabetes, published ahead of print August 2018. doi.org/10.2337/cd18-0004

Goldman JD. Combination of empagliflozin and metformin therapy: A consideration of its place in type 2 diabetes therapy. Clinical Medicine Insights: Diabetes and Endocrinology 2018. Published online ahead of print July 2018. 11; 1-11.

Kerliu L, Goldman JD. Capecitabine and warfarin interaction: A review of literature and recommendations. Pharmacy Times 2018;7(3):10.

Lu B, Goldman JD. Counseling patients with type 1 diabetes. Pharmacy Times 2018;84(2):37-38.

Lu B Goldman JD. Pharmacists and Annual Wellness Visits. Pharmacy Times 2018;84(3):46-47.

Patel D, Goldman JD, Fixed-ratio combination of basal insulin and GLP-1 receptor agonist. Pharmacy Times. 2017; 6(5)12-14.

Valentine V, Goldman JD, Shubrook J. Rationale for initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Published online ahead of print July 2017 doi: 10.1007/s13300-017-0287-7, Diabetes Ther. 2017: 8(4)739-752.

Goldman JD, Trujillo J. iGlarLixi: a fixed-ratio combination of insulin glargine 100U/ml and lixisenatide for the treatment of type 2 diabetes. Published online ahead of print June 2017, Ann Pharmacother. 2017;51(11):990-999. DOI:10.1177/1060028017717281.

Patel D, Goldman JD. Managing diabetes with insulin/glucagon-like peptide-1 receptor agonist combinations: the role of the pharmacist. Pharmacy Times. 2017; June (74-86). Pharmacy Times CE, 2-hours, June 2017. Available at https://pharmacytimes.org/landing/974

Goldman JD, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. doi:10.1080/03007995.2017.1335192, Curr Med Res Opin. 2017;33(10):1821-1831.

Trujillo J, Goldman JD. Lixisenatide, a once daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes. doi: 10.1002/phar.1962. Pharmacotherapy. 2017;37(8):927-943.

Dvorkin Camiel L, Kostka-Rokosz M, Tataronis G, Goldman JD. Performance and perceptions of student teams created and stratified based on academic abilities. AJPE, 2017;81(3):1-7. Article 47.

Taglieri C, Schnee D, Dvorkin Camiel L, Zaiken K, Mistry A, Nigro S, Tataronis G, Patel D, Jacobson S, Goldman JD. Comparison of long-term knowledge retention in lecture-based versus flipped team-based learning course delivery. Currents in Pharmacy Teaching & Learning, 2017;9(3):391-397.

Goldman JD, White J. Advances in basal insulin therapy. Journal of Pharmacy Technology, 2016; published online ahead of print September doi: 10.1177/8755122516667.

Oleck J, Kassam S, Goldman JD. Commentary: Why was inhaled insulin a failure in the market? Diabetes Spectrum, 2016;Aug;29(3):180-184.

Natali K, Goldman JD. Insulin allergy: A case report and review of the literature. Journal of Pharmacy Technology, 2016; published online ahead of print June doi:10.1177/8755122516655544. Journal of Pharmacy Technology 2016:32(5):210-215.

Bialonczyk D, Ourfalian K, Goldman JD. The artificial pancreas- current projects, challenges, and practical considerations. AADE in Practice, 2016; July; Vol 4 (4):50-54.

Dvorkin Camiel L, Mistry A, Schnee D, Tataronis G, Taglieri C, Zaiken K, Patel D, Nigro S, Jacobson S, Goldman JD. Students' attitudes, academic performance and preferences for content delivery in a very large self-care course redesign. AJPE 2016;80(4):Article 67.

Patel D, Charkoudian M, Goldman JD, Couris R. Focus on hypoglycemia: Patient education, disease management and prevention. Nutr Today. 2015;50(6):277-281.

Goldman JD, White J. New insulin glargine 300 U/ml for the treatment of type 1 and type 2 diabetes mellitus. Ann Pharmacother; 2015; published online ahead of print Aug doi: 10.1177/1060028015597915. Ann Pharmacother. 2015;49(10):1153-1161.

Shaikh N, Goldman JD. Current therapy in diabetes. On the Cutting Edge (OTCE) Diabetes Care and Education- Academy of Nutrition and Dietetics; 2015;36(2):4-7.

Goldman JD, Horn D. Overcoming challenges and barriers to insulin therapy in type 2 diabetes. Pharmacy Times; 2015; 81(5):89-100.

Goldman-Levine JD. Combination therapy when metformin is not an option for type 2 diabetes. Ann Pharmacother; 2015; May; Vol. 49(6); 688-699.

Dinsmore S, Grams K, Goldman-Levine JD, Couris RR. An overview of glycemic goals and medications used to manage type 2 diabetes. Nutrition Today; 2015; Jan/Feb;Vol 50(1):40-48.

Sparkes S, Goldman-Levine JD. Breaking down barriers: A second attempt at inhaled insulin. AADE in Practice, 2015; Jan; Vol 3 (1):44-47.

Shaikh N, Goldman-Levine JD. Ready, aim, inject! All about needles and syringes. Diabetes Self-Management 2014; Dec; 16-23.

Goldman-Levine JD, Insulin Pen Problem. Expert Questions and Answers. Diabetes Self-Management: 2014; Oct: 75.

Shaikh N, Goldman-Levine JD. Metformin-induced vitamin B12 deficiency. AADE in practice: 2014; Sept: Vol 2 (5); 38-41.

Shaikh N, Goldman-Levine JD. Insulin injection technique for adults and children with diabetes. Practical Diabetology. 2014; (Sept/Oct) Vol 33(3):19-21.

Sparkes S, Patel D, Goldman-Levine JD. Past, present and future research avenues for metformin: A literature review. Journal of Pharmacy Technology: 2014; Dec; 30;227-234.

Dvorkin Camiel L, Goldman-Levine JD, Kostka-Rokosz M, McCloskey W, Tataronis G. Use of Twitter to Create a Personal Learning Network in a Required Pharmacy Course. Currents in Pharmacy Teaching and Learning. 2014; (July/August) 6 (4); 463-470.

Dvorkin Camiel L, Goldman-Levine JD, Kostka-Rokosz M, McCloskey W. Twitter as an In-class Backchannel Tool in a Large Required Pharmacy Course. Amer J of Pharm Educ. 2014; 78(3) Article 67.

Goldman-Levine JD. Insulin patch pumps: A new tool for type 2. Diabetes Self-Management. 2014; (March/April):10-14.

Sparkes S, Lyden-Fortier S, Goldman-Levine JD. When diet and exercise are just not enough: New medications for weight loss. AADE in practice. 2013:42-45.

Riche D, Goldman-Levine JD. Uncovering and Managing Hypoglycemia: The Pharmacists Role. In Individualizing therapy for the patient with type 2 diabetes: Focus on insulin, emerging therapies, and patient management. US Pharmacist 2013;(suppl): 21-29.

Goldman-Levine JD. Canagliflozin: A new drug for type 2 diabetes. Diabetes Self-Management. 2013; July/Aug:30-32.

Dvorkin Camiel L, Goldman-Levine JD. Herbal products for the treatment of type 2 diabetes. Practical Diabetology. 2013;32(2):25-30.

Goldman-Levine JD, Patel D, Schnee D. Insulin degludec: A novel insulin analogue. Ann Pharmacother. 2013;47(2):269-277.

Patel D, Goldman-Levine JD. Fidaxomicin (Dificid) for clostridium difficile. Am Fam Physician. 2013;87(3):211-212.

Goldman-Levine JD, Dvorkin Camiel L. Patented medicine (complementary and alternative medicine for the treatment of type 2 diabetes). Diabetes Self-Management. 2012;Sept/Oct:42-43. Republished in Practical Diabetology. 2013;Mar/Apr: 25.

Obua U, Goldman-Levine JD. Integrated learning modules to increase involvement in ASHP student society. AJHP. 2012;69:277.

Goldman-Levine JD. Beyond metformin; initiating combination therapy in patients with type 2 diabetes. Pharmacotherapy. 2011;31:44S-53S.

Patel D, Goldman-Levine JD. Doxepin (silenor) for insomnia. Am Fam Physician. 2011;84(4):453-4.

Goldman-Levine JD, Overmedicated (multidrug therapy). Expert Questions and Answers. Diabetes Self-Management: 2010:Nov/Dec:62-63

Edwards KL, Riche DM, Stroup JS, Goldman-Levine JD, Padiyara RS, Cross LB, Kane MP. Insulin glargine and cancer risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy: 2010;30(9):955-965.

Goldman-Levine JD. Beyond metformin; initiating combination therapy in patients with type 2 diabetes. Pharmacotherapy. 2011;31(12 pt 2): 44S-53S.

Goldman-Levine JD, Insulin Pen Doses. Expert Questions and Answers. Diabetes Self Management: 2009:Sept/Oct:55-56.

Cheng J, Bhatt S, Goldman-Levine JD, The benefit and risk of antidiabetic agents used in patients with heart disease. Journal of Pharmacy Practice, published online November 2008, publication in print March/April issue, 2009:22;(2):179-193.

Goldman-Levine JD. Zoledronic acid for osteoporosis. American Family Physician: 2008 :78(4):508-509.

Pareira CE, Goldman-Levine JD. Case Report, letter: Venlafaxine extended release induced alopecia. Annals of Pharmacotherapy:2007;41:1084.

Goldman-Levine JD. Insulin detemir for diabetes mellitus. American Family Physician: 2006;74(2):323-324.

Goldman-Levine JD, Bohlman LG. Ezetimibe/Simvastatin for cholesterol. American Family Physician: 2005;72(10):2081-2082.

Goldman-Levine JD, Lee KW. Insulin Detemir-A New Basal Insulin Analog. The Annals of Pharmacotherapy: 2005;39(3):502-7.

Lemieux A, Goldman-Levine JD, Gorren J. Aripiprizole: An antipsychotic with a novel mechanism of action. J Pharm Technol 2003;19:365-72.

Bechara C, Goldman-Levine JD. Case Report: Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy 2001;21(11):1444-1447.


Honors

Faculty Award for Scholarship of Application, MCPHS
Faculty Award for Scholarship of Integration/Engagement, MCPHS
Faculty Preceptor of the Year Award, MCPHS Biopharmaceutical Industry Fellowship Program
Pharmacy Practice Teacher of the Year, MCPHS
Trustees Award for Teaching Excellence, MCPHS
Recognition of teaching in Family Medicine, AAFP American Academy of Family Physicians
Preceptor of the Year Given by the office of experiential education, MCPHS
Long-Term Faculty Service Award, MCPHS
Fellow, American College of Clinical Pharmacy


Current Professional Memberships, Service & Leadership

The Medical Letter, reviewer 2019 to present
Clinical Diabetes (ADA journal), editorial board, 2018-2020, 2021-2023 reviewer 2015 to present
Diabetes, Obesity and Metabolism, 2015 – present
Journal of Diabetes, 2015 – present
Diabetes Technology and Therapeutics, 2012 – present
Post Graduate Medicine, 2012 - present
Annals of Pharmacotherapy, 2008 to present
American Journal of Lifestyle Medicine, 2008 to present
Annals of Family Medicine, 2007 to present
Prescriber's Letter/Pharmacist's Letter, Specialty Consultant Panel (areas of diabetes, CVD, woman's health and Pharmacotherapy), 2005 to present
Canadian Prescriber's Letter/Pharmacist's Letter 2005 to present
Pharmacotherapy, the Journal of Human Pharmacology and Drug Therapy, 1997 to present
Association of Diabetes Care and Education Specialists (ACDES), 1/03 to present
          AADE, Pharmacy Specialty Practice Group (AADE-SPG), 1/06 to present
Massachusetts Society of Health System Pharmacists (MSHP), 9/98 to 8/07, 10/09 to 12/15
New England Institute for Ambulatory Care Pharmacists (NEIAP)
          Member, Steering Committee, Executive Board; senior advisor, NEIAP, 1/08 to 2012
American College of Clinical Pharmacy (ACCP), 2/96 to present
Endocrine and Metabolism PRN group of ACCP, 1/05 to present
          Networking Committee, Endocrine and Metabolism PRN group of ACCP, 6/06 to present
          Nominations Committee, Endocrine and Metabolism PRN group of ACCP, 2012, 2013
          Research Committee, Endocrine and Metabolism PRN group of ACCP, 2017, 2018
Ambulatory Care PRN group of ACCP, 2/97 to present
Diabetes Educators Educating Massachusetts (DEEM), 1/05 to present
          Programming Committee (DEEM), 1/07 to 2012
          Board of Directors, Recording Secretary (DEEM), 6/07 to 6/08
American Diabetes Association (ADA), 1/03 to 12/07, 1/18 to present
American Association of Colleges of Pharmacy (AACP), 2/97 to 2019